Platelet Rich Fibrin vs Sub Epithelial Connective Tissue and Coronally Advanced Flap Alone in Gingival Recession

This prospective, randomized and controlled clinical trial will compare three modalities of treatment of Miller's class I‐II recession: CAF with PRF versus CAF with Sub‐epithelial tissue graft (SCTG) versus CAF. From each patient a single recession on a single tooth located in the upper arches will be selected. Clinical parameters will be evaluated at base‐line and after 6 months. The protocol is approved by the "G. D'Annunzio" University Ethical Committee. This study is in accordance with the Declaration of Helsinki of 1975. Patients will be recruited from the Unit of Periodontology, Department of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" University of Chieti‐Pescara, Italy. All the volunteer candidates will sign a written informed consent. The trial director will be responsible for randomly assigning patients to treatment after enrollment and will not involve with the clinical interventions or the study measurements. A computer‐generated table will be used to make the random assignment, known only to the trial director. An opaque envelope will conceal group allocation and will be opened just before the intervention surgery. Matching between group and treatment will be performed by a figure extraneous to the experimentation, responsible even for keeping and breaking the blinding, and known only to him. Patients and examiners will be masked to group membership; clinical examiners will be blinded to each other. The study analyst will be also blind to group membership. The analyst will receive the data by groups labeled as A and B. The blind will not be broken until after study completion. At baseline and 6 months after surgery, the following clinical measurements will be recorded on the mid‐buccal point of exposed root surface: Gingival thickness (GT) will be determined using a stent at a mid‐buccal location about 1 mm apical to the pocket depth (PD) level with a #15 endodontic reamer with a silicon disk stop. The soft tissue will be gently pierced at a 90° angle, until hard tissue will be felt. Once the silicon disk will be in contact with the soft tissue surface, it will be fixed by a drop of cyanoacrylate adhesive. After the careful removal of the reamer, the distance between the reamer tip and the stop will be measured with a calliper accurate to the nearest 0.1 mm. The other measurements will be taken with a periodontal probe and will be recorded to the nearest millimetre as follows: Gingival recession (GR) will be measured as the distance from the cement‐enamel junction (CEJ) to the mid‐buccal point of the gingival margin. PD and Clinical attachment level (CAL) will be measured as the distance between the bottom of the pocket and the gingival margin and CEJ, respectively. Keratinized tissue (KT) will be recorded from the mid‐buccal point of the gingival margin to the mucogingival junction. Patient morbidity will be evaluated with a visual analogue scale (VAS). Root coverage esthetic score (RES) (Cairo et al., 2009) will be used for assessing aesthetic outcomes of root coverage procedures. All clinical parameters will be measured by the same investigator. To avoid a calibration probing bias, 60 recession defects will be measured twice within 72 hours. When 90% of the measurements of Gingival thickness will be within 0.3 mm and within 0.5 mm for measurements of GR , calibration will be successfully accepted. 30 ml of blood samples will be collected in 10‐ml tubes without anticoagulant and promptly centrifuged at 3,000 revolutions per minute for 10 minutes. The acellular plasma formed in the upper layer will be washed out. The clot, positioned in the middle of the vial, will be cut off from the lower red corpuscles part. Each PRF clot will be folded onto itself in order to double the thickness, and two membranes placed one over the other (quadruple L‐PRF layer) represented the L‐PRF graft. The connective tissue graft will be harvested from the palatal area on the opposite side of the gingival defect according to Zucchelli et al12. Briefly, two horizontal and two vertical incisions will delimitate the donor area. The graft will be separated from the underlying tissues by the scalpel's blade oriented parallel to the palatal surface to obtain an about 2 mm thick graft. Then, the graft will be de‐epithelialized by a 15c blade and the fatty tissue will be eliminated until obtaining a graft with a thickness of about 1,5 mm. measured by a standard caliper. Exposed and intrasulcular root surface will be accurately scaled using curettes. A modified coronally advanced flap technique (MCAF) will be used to treat the recession defect. The flap will be elevated as follows: an intrasulcular incision will be performed around the selected tooth, the incision moves on contiguous papillae area, avoiding the gingival margin of adjacent teeth. From each side, from coronal to apical, an oblique incision will be carried out. A split‐full‐split dissection will be undertaken until the CEJ could be passively cover by the flap. Both papillae will be de‐epithelialized. The PRFs and the SCTGs will be placed over the exposed root surface of the Test group and Control 1 group respectively. The gingival defect will be fully lined by grafts that mildly cover the neighbouring sub‐papillae areas. The grafts will be fixed applying suture to the periosteum below. In each group, flap will be coronally positioned and sutured over the enamel in a tension‐free position. All patients will receive 2 g/day amoxicillin+clavulanic acid for 6 days for post‐operative infection prevention; 400 mg of oral ibuprofen, twice daily, will control the pain; 0.12% chlorhexidine rinses, twice daily for 3 weeks, will be prescribe to the patients. Sutures will be removed after 14 days. Only 2‐4 weeks after sutures removal, respectively, cautious brushing by a soft toothbrush and interdental brushing will be recommend; meantime, the patients use a 1% chlorhexidine gel twice daily. Weekly supra‐gingival professional hygiene and motivational reinforcement will be administer to the patients for 6 weeks.